Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

European Approval Is Sought for Lirafugratinib in FGFR2-Altered Metastatic Cholangiocarcinoma

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

A marketing authorization application for lirafugratinib, a selective FGFR2 inhibitor for second-line treatment of FGFR2-altered metastatic cholangiocarcinoma, has been submitted to the European Medicines Agency following promising phase 1/2 trial results showing durable efficacy and manageable safety.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You gain new access to the European cancer treatment market with a targeted therapy designed to reduce side effects common in broader FGFR inhibitors. The orphan and breakthrough designations show regulatory favour that can speed your product launch and commercial entry.

◆ Coverage

10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026

◆ Topics

Biotechema-submissionfgfr2-inhibitorcholangiocarcinomaoncology-drugclinical-trial